Complete resection of pulmonary metastases remains the standard treatment for selected patients with isolated pulmonary metastases from extra-thoracic primary malignancies, which is associated with a 5-year survival rate of 21% to 68%[@b1].

When video-assisted thoracic surgery (VATS) was introduced as a minimally invasive surgery, it was quickly utilized in metastasectomy[@b2]. Some new approaches, such as the transxiphoid hand-assisted thoracoscopic surgery (HATS) developed by Mineo[@b3] and Detterbeck[@b4] as well as the trans-diaphragmatic HATS developed by Wright[@b5], have been used in this field. We also developed a HATS procedure for bilateral lung metastasectomy through sternocostal triangle access, which has been reported previously[@b6].

Some authors suggest that the sensitivity of a Computed Tomography (CT)scan is insufficient, and therefore complete manual exploration during thoracotomy should be considered for patients undergoing pulmonary metastasectomy[@b7]. In addition, without manual palpation, the high rate of missing occult metastases during VATS procedures is unacceptable[@b8][@b9]. This study assessed the reliability of our HATS approach in detecting occult metastases when comparing to preoperative helical CT and Positron Emission Tomography- Computed Tomography (PET-CT), and analyzed the survival of the patients who underwent this procedure.

Results
=======

62 patients with pulmonary nodules and a history of solid organ malignancy underwent 65 HATS procedures for pulmonary metastasectomy by the same group of surgeons. Three patients underwent more than one pulmonary metastasectomy for recurrence. The characteristics of the procedures are shown in [Table 1](#t1){ref-type="table"}. The histological information of primary tumors was demonstrated in [Table 2](#t2){ref-type="table"}.

Median follow-up of HATS for bilateral lung metastasectomy through sternocostal triangle access patients was 23.7 months (range 2.4 to 85.6 months). No patient was lost of follow-up. Post-operative recurrences were found in 30 cases. The routine examinations in the follow-up included chest X-ray performed every three months with chest CT scan every six months for five years. Abdominal CT scan was done every six months to twelve months depending on the status of the patients and the classification of primary cancer. Five-year disease-free survival rate in our cohort was shown in [Figure 1](#f1){ref-type="fig"}. One-year, Two-year, Three-year and five-year disease-free survival rates were 84.4%, 61.8%, 44.3% and 31.9%, respectively. Mean disease-free survival time was 40.5 months (log-rank, 95% confidence interval, 32.03 to 48.94). Median disease-free survival period was 27.4 months.

CT scans were performed before 62 HATS procedures. The median interval between metastasectomy and the examination was 13 days (range, 2--52 days). Based on the information of CT scans, 111 pulmonary nodules that were not identified in the images preoperatively were found in 26 cases, and 67 non-imaged malignant nodules were palpated and removed in 14 cases. 29 (29/42) cases who had predicted unilateral metastases at CT scan were confirmed to be unilateral.

PET-CT scans were performed before 43 HATS procedures. The median interval between metastasectomy and the examination was 9 days (range, 2--74 days). If the pulmonary nodules detected by PET-CT were defined as visualization, 76 pulmonary nodules that were not identified in the images preoperatively were found in 20 cases, and 41 non-imaged malignant nodules were palpated and removed in 12 cases. 25 (25/30) cases who had been predicted to have unilateral metastases by PET-CT scan were finally confirmed to be unilateral. While if we change the definition into the high metabolic nodules, 76 pulmonary nodules that were not imaged preoperatively were found in 19 cases, and 43 non-imaged malignant nodules were palpated and removed in 12 cases. 18 (18/25) of the cases who had been predicted to have unilateral metastases were confirmed to be unilateral. Sensitivity and positive predictive value for CT/PET-CT are shown in [Tables 3](#t3){ref-type="table"}.

Discussion
==========

Accurate thoracic imaging brings reliable prediction of the metastatic disease. It is very important to select those patients who would benefit from resection, and palliate those patients who would not[@b10]. Technological progress has resulted in the widespread availability of helical CT scanners[@b11], which has demonstrated superior detection rates compared to conventional CT[@b12]. Overlapping image reconstruction may enhance the number of visible nodules and reduce the number of false-positive nodules attributable to cross sections of pulmonary vessels[@b11]. Therefore, some researchers suggested that helical CT should be the better choice than the palpation of lungs[@b11]. Unfortunately, recent studies have compared helical CT prediction to surgical exploration and reported a high risk of missing lesions in CT scan[@b13].

VATS has been widely used in thoracic surgery in the last decade. Although it is a minimally invasive surgery, VATS makes the palpation of the lungs difficult and incomprehensive, and therefore might be not suitable for pulmonary metastasectomy. The previous studies of VATS showed unsatisfactory results in detection of pulmonary metastatic lesions when compared to our HATS procedure ([Table 4](#t4){ref-type="table"})[@b8][@b9][@b14]. Indeed, VATS is suitable for diagnosis of most undefined peripheral pulmonary nodules including pulmonary metastasis[@b15]. However, the role of therapeutic VATS metastasectomy remains largely unknown[@b12].

The standard approach of metastasectomy is to palpate the lungs at the time of resection in order to completely remove all metastatic deposits[@b1]. Some researchers recommended sternotomy or thoracotomy[@b1]. Studies of these conventional procedures have found that the sensitivity of helical CT in detection of pulmonary metastatic lesions varies from 77% to 88.3% ([Table 4](#t4){ref-type="table"})[@b9][@b14][@b16][@b17][@b18][@b19]. The corresponding figure in our study was 63%. These studies also demonstrated that the sensitivity of PET-CT varies from 64.3% to 67.5% ([Table 5](#t5){ref-type="table"})[@b13][@b20][@b21], while our figure was 66%. The above results demonstrated that our HATS procedure, which may be more minimally invasive compared with sternotomy or thoracotomy[@b6], had similar ability in detection of occult pulmonary metastases.

Although the mortality of conventional thoracotomy is low[@b1], increasing effort has been devoted to new approaches that may reduce the morbidity. Under this circumstance, the HATS procedure, which allows bilateral pleural exploration with a hand, would be an appropriate technique for patients undergoing metastasectomy with curative intent[@b3][@b4][@b5][@b6]. Mineo, Wright and Detterbeck have reported their HATS approaches that allow bilateral manual palpation of the lung in 1999, 2003 and 2004, respectively[@b3][@b4][@b5]. The above three HATS approaches demonstrated analogous results in detection of occult pulmonary metastatic lesions ([Table 4](#t4){ref-type="table"}). As an improvement for HATS, we have some variation in this surgical procedure to overcome some limitations of previous ones. For example, the change of resection from xiphoid appendix to sternocostal triangle access reduced the morbidity of intraoperative rhythm disturbance. Furthermore, keeping the integrity of diaphragm may reduce the risk of post-operative diaphragmatic hernia[@b6].

The analysis of 5,206 patients with pulmonary metastasis confirmed that complete removal of all metastatic deposits was a potentially curative treatment, which is associated with long-term survival[@b1]. The survival data of VATS, obtained from patients with fewer metastases, did not illustrate a frustrating result compared with conventional thoracotomy or HATS procedure ([Table 6](#t6){ref-type="table"})[@b2][@b12][@b15][@b22]. The DFS of metastatic tumors treated with conventional thoracotomy or other HATS procedures, both of which allowed palpation of the lungs, were reported from less than 10 months to 29 months in the literatures ([Table 6](#t6){ref-type="table"}), while the figure in our cohort was similar (27.4 months). There is only one study that reported a better DFS than ours. In this study only the patients with lung metastasis of colorectal cancer were enrolled. In addition, the mean number of pulmonary lesions was 1.73, which was much less than ours (3.88). Therefore, the primary tumors with better prognosis and fewer lung metastases would contribute to the better survival[@b23].

There are several limitations in this study. First, all the data were retrospectively collected. Second, although the radiographic images were reviewed by the same thoracic surgeon and consultant radiologist, the operative findings were recorded according to the operation notes and pathologic reports. Third, the involvement of different surgeons throughout the time of the study may bring in some bias, even though they were all trained in the same group. For example, results of finger palpation or the findings of additional metastatic lesions may not be consistent in all cases. A further well-controlled prospective study is needed to verify the value of our HATS approach in detection of occult pulmonary metastases and the survival data of patients with pulmonary metastases.

In conclusion, our HATS approach provides an easier way for routine bilateral pleural exploration similar to conventional sternotomy or thoracotomy regardless of unilateral or bilateral nodules on preoperative radiographic imaging[@b6]. Using this HATS approach, we detected and removed occult pulmonary metastases, which might contribute to long-term DFS.

Methods
=======

This study was approved by the institutional review board of Sun Yat-sen University Cancer Center (SYSUCC) and informed consent was obtained from each participant. Chart review was performed on 62 consecutive patients who suffered from pulmonary metastases and underwent 65 HATS procedures through sternocostal triangle access between November 2001 and January 2012. Patients clinical and pathological data were obtained. Patients undergoing our HATS procedures were selected according to two mandatory prerequisites: (a) complete control of the primary tumor; (b) absent or resectable extrapulmonary metastases. Exclusion criteria were a history of pleuritis or pleurodesis, or the presence of cardiomegaly or arrhythmia.

CT examination were performed in 62 cases before metastasectomy, while PET-CT examination in 43 cases. The Philips twin flash CT was used from 1995 to 2005 with 10-mm slice collimation and 10-mm reconstruction. The Philips Brilliance 16 CT (Philips Healthcare, Andover, MA) with 5-mm slice collimation and 5-mm reconstruction was introduced in 2005. A Toshiba Aquilion 64 CT scanner (Toshiba American Medical Systems Inc, Tustin, CA) with 2-mm slice collimation and 5-mm reconstruction was introduced in 2009 and a Discovery ST16 PET-CT made by General Electric (GE Healthcare, Piscataway, NJ) was introduced in 2005.

No patients turned out to have non-small cell lung cancer among the ones whose primary tumors were not. All the radiographic images were reviewed by the same thoracic surgeon and consultant radiologist, and the number, type of the pulmonary nodules that were palpated and removed or detected by CT/PET-CT were recorded. The radiologist would record each nodule which was suspicious regardless of its size.

Sensitivity was determined by the number of true-positive metastases identified by the radiologist divided by the number of total metastases identified by pathology (true positives + false negatives). Positive predictive value was determined by the number of true-positive metastases identified by the radiologist divided by the total number of nodules called by the radiologist (true positives + false positives). Because it was not possible to quantify true negative findings for pulmonary nodules in patients with multiple lesions, the specificity and negative predictive value could not be calculated.

Statistics analyses were performed on all operations regardless of the fact that how many operations each patient had. Disease-free survival (DFS) curves were estimated using the Kaplan-Meier method. Time to event was calculated from the date of resection of the pulmonary metastases to the time of diagnosis of new metastases, was reported in this article. Data analysis was performed using SPSS 18.0 (PASW Statistics 18) for Windows (SPSS Inc, Chicago, IL).
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###### The characteristics of the procedures

  Characteristic                                      Procedures for Pulmonary Metastasectomy (n = 65)  
  -------------------------------------------------- -------------------------------------------------- -----
  Sex (%)                                                                                                  
  Male                                                                       42                          65%
  Female                                                                     23                          35%
  CT/PET-CT unilateral/bilateral metastases (%)                                                            
  Unilateral                                                                 39                          60%
  Bilateral                                                                  26                          40%
  Pathological unilateral/bilateral metastases (%)                                                         
  Unilateral                                                                 33                          51%
  Bilateral                                                                  32                          49%
  Age (years)                                                                                              
  Median                                                                     49                            
  Range                                                                    12--88                          
  Mean                                                                       48                            
  Follow-up(months)                                                                                        
  Median                                                                     19                            
  Range                                                                    1--86                           
  Mean                                                                       27                            
  Length of stay (days)                                                                                    
  Median                                                                     6                             
  Range                                                                    2--24                           
  Mean                                                                       7                             
  Resected lesion size (mm)                                                                                
  Mean                                                                       12                            
  Median                                                                     8                             
  Range                                                                    1--80                           
  No. of resected lesion (metastases/benign)                                                               
  Metastases                                                                183                          73%
  Benign                                                                     69                          27%

###### Primary Tumor Types

  Types of Primary Cancer                Number of Procedures   Percent (%)
  ------------------------------------- ---------------------- -------------
  Colorectal Carcinoma                            18               27.7
  HCC                                             10               15.4
  Renal Carcinoma                                 5                 7.7
  NPC                                             4                 6.2
  Cervical Carcinoma                              4                 6.2
  Lung Cancer                                     3                 4.6
  Osteosarcoma                                    3                 4.6
  Melanoma                                        2                 3.1
  Hysteromyoma                                    2                 3.1
  Thyroid Cancer                                  1                 1.5
  Breast Cancer                                   1                 1.5
  Carcinoma of Urinary Bladder                    1                 1.5
  Esophageal Carcinoma                            1                 1.5
  Malignant Uteri Chorion-Epithelioma             1                 1.5
  Synovial Sarcoma                                1                 1.5
  Nephroblastoma                                  1                 1.5
  Duodenal Carcinoma                              1                 1.5
  Gastric Cancer                                  1                 1.5
  Adrenal Pheochromocytoma                        1                 1.5
  Testicular Mixed Germ Cell Tumor                1                 1.5
  Liposarcoma                                     1                 1.5
  Tongue Cancer                                   1                 1.5
  Nasal Malignant Mixed Tumor                     1                 1.5
  Total                                           65                100

###### Nodules Revealed at Surgery and on Computed Tomography/Positron Emission Tomography- Computed Tomography

  Procedures enrolled to the analysis(N = 65)                                
  --------------------------------------------- ----- ----- ----- ----- ---- -----
  Nodules                                        252   139   113   55%   21   87%
  Metastases                                     183   126   57    69%   33   79%

  Procedures with CT scan(N = 62)                                
  --------------------------------- ----- ----- ----- ----- ---- -----
  Nodules                            246   135   111   55%   5    96%
  Metastases                         182   115   67    63%   15   88%

  Procedures with PET-CT (N = 43)                             
  --------------------------------- ----- ---- ---- ----- --- -----
  Nodules                            169   93   76   55%   1   99%
  Metastases                         120   79   41   66%   8   91%

  Procedures with CT&PET(N = 40)                               
  -------------------------------- ----- ----- ---- ----- ---- -----
  Nodules                           163   104   59   64%   5    95%
  Metastases                        118   78    40   66%   18   81%
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PPV: Positive Predictive Value.

###### Sensitivity of Helical CT in Detecting Pulmonary Metastases

  Approaches                         Study                  N    No. of metastases              Sensitivity (%)
  ------------------- ----------------------------------- ----- ------------------- ----------------------------------------
  Thoracotomy             Kayton et al 2006\[[@b16]\]      54           209                           87.6
  Thoracotomy            Nakajima et al 2007\[[@b14]\]     43           130                           85.4
  Thoracotomy              Kang et al 2008\[[@b17]\]       27           198                            77
  Thoracotomy          Pfannschmidt et al 2008\[[@b18]\]   125          331                           83.7
  Thoracotomy              Ellis et al 2011\[[@b9]\]       ---          73                            88.3
  Thoracotomy             Chung et al 2011\[[@b19]\]       120          368          26.7% (32/120) have occult metastases
  VATS                   McCormack et al 1996\[[@b8]\]     18           19                [\*](#t4-fn3){ref-type="fn"}
  VATS                   Nakajima et al 2007\[[@b14]\]     79           120                            90
  VATS                     Ellis et al 2011\[[@b9]\]       ---          35                [\*](#t4-fn3){ref-type="fn"}
  Transxiphoid HATS        Mineo et al 1999\[[@b3]\]       13           21                            76.2
  Transxiphoid HATS      Ambrogi et al 2000\[[@b10]\]      22           49                             84
  Transxiphoid HATS       Mineo et al 2001\[[@b24]\]       29           60                            81.7
  Substernal HATS         Detterbeck et al 2004\[4\]       16           ---           18.8% (3/16) have occult metastases
  Transxiphoid HATS       Mineo et al 2007\[[@b25]\]       71           178                           87.1
  Mix 1                  Parsons et al 2004\[[@b11]\]      41           88                             78
  Mix 2                   Parsons et al 2007\[[@b7]\]      60           135                            60
  Our HATS                       Current study             62           182          6322.6% (14/62) have occult metastases

N: Number of cases.

---: No data obtained.

\*: The number of pulmonary nodules palpated and removed is less than the number of pulmonary nodules detected on CT scan.

Mix1: The approaches consists of sternotomy (n = 19), unilateral thoracotomy (n = 11), VATS with a substernal handport (n = 11).

Mix2: The approaches consists of sternotomy (n = 30), unilateral thoracotomy (n = 19), VATS with a substernal handport (n = 11).

###### Sensitivity of PET-CT in Detecting Pulmonary Metastases

  Approaches                 Study                N    No. of metastases               Sensitivity(%)
  ------------- ------------------------------- ----- ------------------- -----------------------------------------
  Thoracotomy     Fortes et al 2008\[[@b20]\]    104          154                           67.5
  Thoracotomy    Cerfolio et al 2009\[[@b13]\]   57           67                            64.3
  Thoracotomy    Cerfolio et al 2011\[[@b21]\]   152          ---           21.1% (32/152) have occult metastases
  Our HATS               Current study           43           116          66%27.9% (12/43) have occult metastases

N: Number of cases.

---: No data obtained.

###### Disease-free survival of metastasis tumor

  Approaches                       Study                 N    DFS (months)   Survival Rate                
  ------------------- -------------------------------- ----- -------------- --------------- ------ ------ ------
  Thoracotomy          Mutsaerts et al 2002\[[@b22]\]   19        \<10            ---         42    ---    ---
  Thoracotomy           Nakajima et al 2008\[[@b2]\]    71         27            57.6        ---    26.2   21.1
  Thoracotomy          Carballo et al 2009\[[@b15]\]    135       24.8           87.4        ---    67.9   58.8
  Thoracotomy            Nakas et al 2009\[[@b12]\]     27         29             ---        ---    ---    ---
  VATS                 Mutsaerts et al 2002\[[@b22]\]   16        \<10            ---         50    ---    ---
  VATS                  Nakajima et al 2008\[[@b2]\]    72        23.8           64.6        ---    42.6   34.4
  VATS                 Carballo et al 2009\[[@b15]\]    36        25.6           91.7        ---    69.6   69.6
  VATS                   Nakas et al 2009\[[@b12]\]     25         20             ---        ---    ---    ---
  Transxiphoid HATS      Mineo et al 2001\[[@b24]\]     29         19             ---        ---    ---    ---
  Transxiphoid HATS      Mineo et al 2007\[[@b25]\]     71         12             ---        ---    ---    ---
  Our HATS                     Current study            65        27.4           84.4        61.8   44.3   31.9

N: Number of cases.

---: No data obtained.
